Brooke Esteves

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen et al. · Journal of Clinical Oncology · 2013 · 443 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 372 citations · Full text

Medicine, Oncology, Pharmacology +15

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Dmitry Nosov, Brooke Esteves, Oleg Lipatov et al. · Journal of Clinical Oncology · 2012 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava et al. · Clinical Cancer Research · 2011 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

Robert J. Motzer, Dmitry Nosov, Tim Eisen et al. · Journal of Clinical Oncology · 2012 · 95 citations

Medicine, Oncology, Pharmacology +17